[The bactericidal action of human neutrophils on meningococci in vitro].
32 Russian patients with late complement component deficiency (LCCD) were immunize with tetravalent meningococcal polysaccharide vaccine (A + C + W135 + Y). Their immune response and infectious morbidity rate were followed for 6 years and the partial protective efficacy of vaccination was demonstrated. As the antibody-mediated complement-induced bactericidal activity of plasma was completely absent in persons with LCCD, the bactericidal action of human neutrophils on meningococci of groups A, W135 and B was studied under the conditions of incubation with serum samples collected from persons with LCCD before and after vaccination. In LCCD serum alone the exponential growth of meningococci was observed, while the addition of human neutrophils resulted in the essential inhibition of the growth of meningococci (up to their complete elimination). The proportion of serum samples stimulating the elimination of group A and W 135 meningococci by neutrophils was almost 40% of the serum samples collected before vaccination and significantly increased among the serum samples collected after vaccination (up to 84%) or revaccination (up to 90%). At the same time the capacity of an individual serum sample to promote the bactericidal effect of neutrophils against meningococci correlated with its content of specific anti-polysaccharide IgG and IgM antibodies, as well as antibodies to the inner core of lipopolysaccharide. The interaction of neutrophils with meningococci was significantly inhibited after incubation in heat-inactivated serum, suggesting that this interaction was partly mediated along the following path: the binding of IgM and IgG antibodies with bacteria--the activation of complement and the deposition of C3 complement on bacteria--the binding of meningococci with CR3 receptors of neutrophils.
Platonov
A E
AE
Central Research Institute of Epidemiology, Moscow, Russia.
Vershinina
I V
IV
Käyhty
H
H
Fijen
C A
CA
Kuijper
E J
EJ
D001428:Bacterial Vaccines / Q000276:immunology; D001770:Blood Bactericidal Activity / Q000276:immunology*; D003165:Complement System Proteins / Q000172:deficiency; D006801:Humans; D007111:Immunity, Cellular; D007153:Immunologic Deficiency Syndromes / Q000276:immunology; D008589:Meningococcal Infections / Q000276:immunology / Q000517:prevention & control; D009345:Neisseria meningitidis / Q000276:immunology*; D009504:Neutrophils / Q000276:immunology*; D013997:Time Factors; D017778:Vaccines, Combined / Q000276:immunology
D001428:Bacterial Vaccines; D017778:Vaccines, Combined; D003165:Complement System Proteins
Bakteritsidnoe deĭstvie neĭtrofilov cheloveka na meningokokki in vitro.